Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
NanoSmart® Pharmaceuticals and UCLA Enter Collaboration Agreement for Pediatric Cancer Drug Development

LAGUNA HILLS, Calif., Jan. 16, 2013 /PRNewswire/ -- NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

"We are very excited to work closely with Dr. Noah Federman and his colleagues at UCLA, as they will provide access to an extraordinary level of research, development and clinical resources," said Dr. James Smith, President of NanoSmart Pharmaceuticals.  "Their expertise in the development of nanotechnology-based drugs will enable us to continue making efficient progress towards commercializing these products."

NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of tumors. When combined with already FDA-approved cancer drugs, this patented technology allows for the creation of a broad range of next-generation, safer, and more effective cancer drug products.

"Despite the extensive research into new drug formulations, the pace of advancing benefit to this patient population is unfortunately slowing," said Dr. Noah Federman, Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, a part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center; and Assistant Professor of Pediatrics, Hematology/Oncology at Mattel Children's Hospital at UCLA. "We are pleased to collaborate with NanoSmart to help drive the development of these much-needed products."

UCLA's Jonsson Comprehensive Cancer Center (http://www.cancer.ucla.edu) is among the nation's largest and top-ranked comprehensive cancer research centers. With more than 240 researchers and clinicians, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies.

Mattel Children's Hospital UCLA, one of the highest-rated children's hospitals in California and a vital component of Ronald Reagan UCLA Medical Center, offers a full spectrum of primary and specialized medical care for infants, children, and adolescents. The hospital's mission is to provide state-of-the-art treatment for children in a compassionate atmosphere and to improve the understanding and treatment of pediatric diseases.

NanoSmart Pharmaceuticals, Inc. (www.nanosmartpharma.com) is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases. NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of tumors and other diseases. NanoSmart has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of its lead candidate drug products.

This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

SOURCE NanoSmart Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
Maintaining lower development environments can become an unbearable headache. Changes to an application, service or API are seldom completely testable, leaving us to discover broken code when it’s too late. This lack of visibility into application dependencies severely limits early cod...
In this report Enterprise Management Associates (EMA) analysts explore the ways in which gaining visibility and control over high-privilege access helps organizations achieve regulatory compliance, assure responsible governance, and improve security all while reducing IT operational co...
More and more enterprises today are doing business by opening up their data and applications through APIs. Though forward-thinking and strategic, exposing APIs also increases the surface area for potential attack by hackers. To benefit from APIs while staying secure, enterprises and se...
SYS-CON Events announced today that ActiveState, providers of Stackato, the platform for the agile enterprise, has been named “Silver Sponsor” of SYS-CON's 2nd DevOps Summit, which will take place on June 10–12, 2014, at the Javits Center in New York City, New York. ActiveState believ...
Many cloud hosting providers have achieved ticket-of-entry credibility in the data warehousing industry by building simple colocation centers. A first-tier database as a service (DBaaS) contender, however, is set apart by a value-added service approach that is strategic, consultative a...
VASCO Data Security International, Inc., has announced on Tuesday that it will release its Q1 2014 results on Thursday, April 24th. On April 24, at 10.00 am EDT/16.00 CET, VASCO will hold a conference call, which will be streamed on the VASCO website. Mr. T. Kendall Hunt, Chairman an...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE